According to GDSC database, we found that high expression of CCNA2 could make cancer more sensitive to irinotecan (target at TOP1), topetecan (target at TOP1), TKI258 (target at FGFR), PF2341066 (target at c-MET), paclitaxel (target at TUBB1), TAE684 (target at ALK), panobinostat (target at HDAC), RAF265 (target at RAF), nutlin-3 (target at MDM2), sorafenib (target at RTK), and PD-032991 (target at CDK4) and resistant to AZD6244 (target at MEK) (Figure 11(b)). This evidence concerns the gene MET and cancer.